Repare Therapeutics Inc.

RPTX

Repare Therapeutics Inc.

RPTX

Insider Sentiment (TTM):

Last Purchase:2023-11-16Last Sale:2025-03-12Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2025-12-31Institutional Shares Owned:24,438,387Shares Outstanding:42,965,529Institutional Ownership Pct.:56.88%

Earnings Market Reaction:

Filing Date:2025-11-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets
Cash And Cash Equivalents At Carrying Value	73	68	84	85	81	80	103	111	107	116	121	160
Marketable Securities Current	40	42	40	68	99	128	134	112	143	165	193	184
Receivables Long Term Contracts Or Programs	-	-	-	-	-	-	-	-	-	-	4	2
Other Receivables	-	-	-	-	-	-	-	-	-	-	1	2
Assets Current
Assets Current	124	127	140	171	200	229	255	244	275	292	326	354
Income Tax Receivable	-	-	-	-	-	-	-	-	-	2	-	-
Income Taxes Receivable	2	10	10	11	11	11	11	11	16	-	-	0
Other Receivables Net Current	6	5	2	2	3	4	3	4	4	5	-	4
Prepaid Expense Current	4	2	5	6	7	6	3	5	6	4	4	6
Property Plant And Equipment Net	0	0	1	2	3	3	4	4	5	5	5	4
Operating Lease Right Of Use Asset	0	1	1	2	2	2	3	3	4	4	5	5
Income Taxes Receivable Noncurrent	0	1	1	1	1	1	2	2	2	-	-	0
Equity Securities Without Readily Determinable Fai…	2	2	-	-	-	-	-	-	-	-	-	-
Other Assets Noncurrent	1	1	0	0	0	0	0	0	0	0	0	0
Deferred Income Tax Assets Net	-	-	-	-	-	-	-	-	-	-	-	0
Assets	127	130	144	177	206	235	263	254	286	302	336	364
Liabilities And Stockhold…
Accounts Payable Current	1	4	2	4	11	7	7	2	5	5	4	0
Accrued Liabilities And Other Liabilities	10	12	15	20	18	22	20	24	21	22	17	22
Liabilities Current
Liabilities Current	12	20	19	25	31	31	31	39	49	53	81	79
Operating Lease Liability Current	0	1	1	2	2	2	2	2	2	2	2	2
Contract With Customer Liability Current	-	-	-	0	0	0	1	10	20	24	53	53
Accrued Income Taxes Current	-	-	-	-	-	-	-	0	0	0	5	1
Operating Lease Liability Noncurrent	0	0	0	0	0	0	1	1	2	2	3	3
Contract With Customer Liability Noncurrent	-	-	-	0	0	0	0	2	2	1	1	3
Liabilities	12	20	19	25	31	32	31	42	53	56	85	85
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	490	490	490	487	487	486	486	483	483	483	483	482
Stockholders Equity
Stockholders Equity	115	110	125	151	175	204	232	212	233	245	251	280
Warrants And Rights Outstanding	0	0	0	0	-	-	-	0	-	-	-	-
Additional Paid In Capital Common Stock	86	85	83	82	77	72	66	62	56	49	43	37
Accumulated Other Comprehensive Income Loss Net Of…	0	-0	0	0	0	-0	-0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-461	-465	-448	-418	-389	-355	-320	-333	-305	-286	-274	-239
Liabilities And Stockholders Equity	127	130	144	177	206	235	263	254	286	302	336	364
Preferred Stock No Par Value	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock No Par Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Issued	43	43	43	43	43	42	42	42	42	42	42	42
Shares Outstanding	43	43	43	43	43	42	42	42	42	42	42	42

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	2.80%	0.70%	4.90%	8.79%	10.10%	27.69%	34.24%	55.76%	-	-	-	-
2024	6.10%	0.61%	20.12%	-9.91%	6.50%	7.74%	-6.02%	-63.04%	-65.04%	-9.48%	7.76%	13.79%
2023	8.45%	0.47%	-11.97%	14.73%	43.47%	-60.81%	45.16%	99.18%	77.90%	-25.91%	-52.27%	-46.21%
2022	-	-	-	-	-	-	-	-	-	-5.37%	-6.63%	-7.61%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Liquidity Ratios
Current Ratio	10.71	6.30	7.42	6.77	6.45	7.27	8.33	6.24	5.62	5.48	4.02	4.50
Quick Ratio	10.40	6.18	7.18	6.53	6.23	7.08	8.22	6.11	5.50	5.40	3.97	4.43
Working Capital	112.81M	106.49M	121.42M	145.86M	169.32M	197.09M	224.10M	204.61M	226.12M	238.67M	244.59M	275.36M
Leverage & Debt
Debt to Equity	0.10	0.18	0.15	0.17	0.18	0.16	0.13	0.20	0.23	0.23	0.34	0.30
Debt Ratio	0.09	0.15	0.13	0.14	0.15	0.13	0.12	0.16	0.19	0.19	0.25	0.23
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.68	-2.56	-3.00	-2.00	-1.98	-1.61	-1.04	-2.23	-2.31	-0.07	-0.70	-0.69
Free Cash Flow Per Share TTM	-1.63	-2.41	-2.76	-1.80	-1.83	-1.88	-2.01	-3.07	-3.13	-0.26	-0.13	-0.09
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-14.10%	60.34%	179.90%	-9.71%	-13.73%	2,121.82%	56.32%	222.91%	279.39%	-97.66%	-75.69%	-72.83%
EPS Growth (1Y)	-15.12%	58.56%	177.55%	-10.39%	-14.44%	2,103.19%	55.60%	221.60%	277.98%	-97.67%	-75.79%	-75.49%
Calculated Values
Free Cash Flow TTM	-70.15M	-103.34M	-117.51M	-76.45M	-77.68M	-80.01M	-84.90M	-129.10M	-131.90M	-11.14M	-5.49M	-3.72M
Net Debt	-72.83M	-67.66M	-84.46M	-84.72M	-80.54M	-79.82M	-103.22M	-111.27M	-107.37M	-115.54M	-121.46M	-159.52M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-03-12Sale

Owner: Forte, Steve

Title: EVP, CHIEF FINANCIAL OFFICER

Shares: 6,884

Price/Share: $1.14

Value: $7,847.76

Shares Owned: 54,786

Relationship: Officer

Ownership: Direct

2025-03-12Sale

Owner: Koehler, Maria

Title: EVP, CHIEF MEDICAL OFFICER

Shares: 3,596

Price/Share: $1.14

Value: $4,099.44

Shares Owned: 227,813

Relationship: Officer

Ownership: Direct

2025-03-12Sale

Owner: Segal, Lloyd Mitchell

Title: PRESIDENT AND CEO

Shares: 21,179

Price/Share: $1.14

Value: $24,144.06

Shares Owned: 124,394

Relationship: Director,Officer

Ownership: Direct

2025-03-12Sale

Owner: Zinda, Michael

Title: EVP, CHIEF SCIENTIFIC OFFICER

Shares: 5,611

Price/Share: $1.14

Value: $6,396.54

Shares Owned: 80,297

Relationship: Officer

Ownership: Direct

2024-04-01Sale

Owner: Segal, Lloyd Mitchell

Title: PRESIDENT AND CEO

Shares: 2,491

Price/Share: $4.63

Value: $11,533.33

Shares Owned: 107,558

Relationship: Director,Officer

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-03-12	Forte, Steve	Officer	EVP, CHIEF FINANCIAL OFFICER	Direct	Sale	6,884	1.14	$7,847.76	54,786	4
2025-03-12	Koehler, Maria	Officer	EVP, CHIEF MEDICAL OFFICER	Direct	Sale	3,596	1.14	$4,099.44	227,813	4
2025-03-12	Segal, Lloyd Mitchell	Director,Officer	PRESIDENT AND CEO	Direct	Sale	21,179	1.14	$24,144.06	124,394	4
2025-03-12	Zinda, Michael	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	5,611	1.14	$6,396.54	80,297	4
2024-04-01	Segal, Lloyd Mitchell	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	2,491	4.63	$11,533.33	107,558	4
2024-04-01	Forte, Steve	Officer	EVP, CHIEF FINANCIAL OFFICER	Direct	Sale	789	4.61	$3,637.29	44,775	4
2024-04-01	Koehler, Maria	Officer	EVP, CHIEF MEDICAL OFFICER	Direct	Sale	300	4.66	$1,398.00	231,409	4
2024-04-01	Zinda, Michael	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	410	4.66	$1,910.60	71,908	4
2024-03-27	Zinda, Michael	Officer	EVP, CHIEF SCIENTIFIC OFFICER	Direct	Sale	450	4.62	$2,079.00	72,768	4
2024-03-27	Koehler, Maria	Officer	EVP, CHIEF MEDICAL OFFICER	Direct	Sale	500	4.62	$2,310.00	232,209	4
2024-03-27	Forte, Steve	Officer	EVP, CHIEF FINANCIAL OFFICER	Direct	Sale	825	4.62	$3,811.50	42,212	4
2024-03-27	Segal, Lloyd Mitchell	Director,Officer	PRESIDENT AND CEO	Indirect	Sale	2,650	4.63	$12,269.50	83,866	4
2023-11-16	Biotechnology, Value Trad…	TenPercentOwner	-	Direct	Purchase	295,745	5.38	$1,591,108.10	5,309,432	4
2023-11-02	Biotechnology, Value Trad…	Other	-	Direct	Purchase	783,709	3.60	$2,821,352.40	4,662,402	4
2023-06-08	Zinda, Michael	Officer	EVP, Chief Scientific Officer	Direct	Sale	2,869	12.02	$34,485.38	60,118	4
2023-06-06	Zinda, Michael	Officer	EVP, Chief Scientific Officer	Direct	Sale	1,200	12.04	$14,448.00	69,391	4
2022-12-09	Jerel, Davis	Director	-	Indirect	Sale	250,000	16.00	$4,000,000.00	2,094,451	4
2022-06-13	Biotechnology, Value Fund…	TenPercentOwner	-	Direct	Purchase	149,161	12.73	$1,898,819.53	4,443,423	4
2022-06-06	Bvf, Ii Gp Llc, Bvf Gp Ho…	TenPercentOwner	-	Direct	Purchase	6,869	13.21	$90,739.49	4,368,757	4
2022-06-03	Versant, Vantage I, L.P.,…	TenPercentOwner	-	Indirect	Sale	750,000	12.25	$9,187,500.00	44,065	4
2022-06-03	Versant, Venture Capital …	TenPercentOwner	-	Indirect	Sale	750,000	12.25	$9,187,500.00	44,065	4
2022-06-03	Jerel, Davis	Director,TenPercentOwner	-	Indirect	Sale	750,000	12.25	$9,187,500.00	44,065	4
2022-05-18	Bvf, Gp Holdings Llc, Bvf…	Other	-	Direct	Purchase	420,000	8.50	$3,570,000.00	3,350,950	4
2022-03-15	Zinda, Michael	Officer	EVP, Chief Science Officer	Direct	Sale	533	11.30	$6,022.90	46,041	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2025-12-31

56.88%

Inst. Shares: 24,438,387

Shares Outstanding: 42,965,529

2025-09-30

62.12%

Inst. Shares: 26,691,176

Shares Outstanding: 42,965,529

2025-06-30

63.05%

Inst. Shares: 27,062,808

Shares Outstanding: 42,921,936

2025-03-31

67.73%

Inst. Shares: 28,846,076

Shares Outstanding: 42,591,730

2024-12-31

70.73%

Inst. Shares: 29,995,968

Shares Outstanding: 42,411,085

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-12-31	24,438,387	42,965,529	56.88%
2025-09-30	26,691,176	42,965,529	62.12%
2025-06-30	27,062,808	42,921,936	63.05%
2025-03-31	28,846,076	42,591,730	67.73%
2024-12-31	29,995,968	42,411,085	70.73%
2024-09-30	31,673,639	42,452,617	74.61%
2024-06-30	33,053,944	42,445,462	77.87%
2024-03-31	34,801,107	42,234,001	82.40%
2023-12-31	35,203,426	42,093,293	83.63%
2023-09-30	33,382,075	42,102,685	79.29%
2023-06-30	32,865,648	42,089,530	78.09%
2023-03-31	29,587,481	42,040,674	70.38%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Repare Therapeutics Inc. (RPTX) — SEC Financial Statements & Analysis

Repare Therapeutics Inc. (RPTX) is a pharmaceutical preparations company, incorporated in Z4. Repare Therapeutics Inc. trades on Nasdaq as: RPTX. Based on its latest SEC filing (Form 10-Q, period ending 2025-09-30), Repare Therapeutics Inc. reported a Debt-to-Equity ratio of 0.10x. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.10x

Data as of 2025-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Repare Therapeutics Inc. in?

Repare Therapeutics Inc. (RPTX) operates in the Pharmaceutical Preparations industry.

What exchange does RPTX trade on?

Repare Therapeutics Inc. (RPTX) trades on the Nasdaq.

Where is Repare Therapeutics Inc. incorporated?

Repare Therapeutics Inc. is incorporated in Canada (Federal Level).